Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,524 signal articles · 27 in last 24h · 122,294 total before filter · latest 5h ago
27last 24h
1251last 7d
210● bullish (7d)
151● bearish (7d)
205publishers
AllMacro211Earnings429M&A97Regulatory24Product9Analyst11
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
U.S. Stocks Down as Oil Rises Ahead of Inflation Data
The Wall Street Journal11d agoneutral
U.S. Stocks Down as Oil Rises Ahead of Inflation Data

U.S. stocks slid as negotiations about the future of the Strait of Hormuz remain deadlocked, pushing oil prices up ahead of key inflation data Wednesday. Oil futures rose $1.07, or 1.3%, to $83.20 a barrel, amid signs that the Middle East conflict may escalate again. The yield on the 10-year Treasury note declined 0.014 percentage point to 4.683%.

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?
Simply Wall St.11d agoneutral
AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie’s share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year total...

AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results
Simply Wall St.11d agoneutral
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results

Why ABCL635’s Phase 2 data matters for AbCellera Biologics stock AbCellera Biologics (ABCL) has become a focus for many biotech investors after announcing that ABCL635 met primary endpoints in a Phase 2 trial for menopause related hot flashes. The single dose of ABCL635 produced statistically significant reductions in both the frequency and severity of vasomotor symptoms versus placebo and was reported as well tolerated, with additional benefits in sleep and patients’ overall perception of...

Moody's (MCO) Faces Private Credit Risk, Is The Stock Already Fully Valued?
Simply Wall St.11d agoneutral
Moody's (MCO) Faces Private Credit Risk, Is The Stock Already Fully Valued?

Mounting risks in private credit, especially weaker recoveries on software loans flagged by SLR Capital Partners, have pushed investors to reassess how Moody's (MCO) is exposed to credit conditions and changing expectations around default outcomes. See our latest analysis for Moody's. Moody's share price is US$478.14, with a 90 day share price return of 5.84% but a year to date share price return that is down 4.18%, while the 3 year total shareholder return of 44.64% contrasts with a 1 year...

Redwire (RDW) Is Up 36.1% After Record Q2 Sales And Backlog - Has The Bull Case Changed?
Simply Wall St.11d agoneutral
Redwire (RDW) Is Up 36.1% After Record Q2 Sales And Backlog - Has The Bull Case Changed?

In the past week, Redwire Corporation reported second-quarter 2026 results showing sales rising to US$117.07 million from US$61.76 million a year earlier, with the net loss narrowing to US$40.97 million from US$96.98 million and full-year 2026 revenue guidance reaffirmed at US$450 million to US$500 million. Beyond the headline growth, Redwire emphasized a record contracted backlog and improving loss per share, suggesting its space and defense contract base is deepening even as the business...

Ouster (OUST) Lands Utah BlueCity Expansion Across 160 More Intersections
Simply Wall St.11d agoneutral
Ouster (OUST) Lands Utah BlueCity Expansion Across 160 More Intersections

Ouster (NasdaqGS: OUST) secured a multimillion dollar contract expansion with the Utah Department of Transportation to deploy its BlueCity lidar traffic management solution. The agreement covers BlueCity deployments at 160 additional intersections across Utah for advanced traffic management. The rollout uses Ouster's next generation OS1 Max Rev8 lidar sensors, which include long range detection and native color capabilities. This contract is tied directly to Ouster's focus on intelligent...

5 Insightful Analyst Questions From onsemi’s Q2 Earnings Call
StockStory11d agoneutral
5 Insightful Analyst Questions From onsemi’s Q2 Earnings Call

onsemi’s second quarter performance was driven by surging demand in its AI data center segment and ongoing portfolio reshaping efforts. Management pointed to robust momentum in advanced power systems, particularly for AI workloads, and highlighted content expansion in automotive and energy infrastructure. CEO Hassane El-Khoury explained that, “AI data center remains our fastest-growing market,” noting wins with key hyperscalers and design-ins with leading global customers. The company also cited

What Is The Market Really Expecting From AVGO Stock?
Trefis11d agoneutral
What Is The Market Really Expecting From AVGO Stock?

At $422, Broadcom (AVGO) is being priced to deliver 26% revenue growth annually for the next 5 years simply to defend today's 68.4x multiple. That sits below the 32% the business is currently growing at, which is the unusual part. The multiple has already priced in a slowdown that has not yet appeared.

Spotify Just Legalized Fan Remixes, So What Does It Mean For SPOT?
Insider Monkey11d agoneutral
Spotify Just Legalized Fan Remixes, So What Does It Mean For SPOT?

On August 4, Spotify (NYSE:SPOT) and Merlin announced a licensing agreement that lets independent artists opt into Spotify’s upcoming fan-made covers and remixing tool. It sounds like a minor feature rollout, but the stock has been under pressure for most of the year, and this is one of several engagement bets management is leaning on […]

Intel’s CFO called his shot, but shareholders pay the price
TheStreet11d agoneutral
Intel’s CFO called his shot, but shareholders pay the price

Intel Corp. (INTC) priced an upsized $20 billion stock offering at $95 a share on Tuesday, Aug. 11, raising $5 billion more than the $15 billion plan it announced just one trading day earlier. Wall Street treated this as breaking news. It wasn’t. Intel’s own finance chief told investors this could ...

CoreWeave Took a Step in the Right Direction, Gil Luria Says
Bloomberg11d agoneutralVIDEO
CoreWeave Took a Step in the Right Direction, Gil Luria Says

Gil Luria, head of technology research at D.A. Davidson, reacts to CoreWeave topping analysts' estimates for second-quarter sales after signing up more customers in a booming market, with sales more than doubling to $2.58 billion. He speaks on "Bloomberg The Close."